APOLLO1: Australian Peritoneal Organoid guided therapy to Lengthen Life in patients without Opportunity for Cure: a pilot trial.
This new concept was presented and reviewed at the Lower GI Working Party Meeting on 13 March. APOLLO1 aims to collect and grow peritoneal deposits from patients with unresectable peritoneal cancer and then subject them to high drug sensitivity testing and whole exome sequencing. The results will inform the patient’s standard of care. A pilot phase trial has been undertaken. This was an open-labelled trial of 15 patients which was partly funded by NHMRC. As a result of the pilot study, 2 of the 15 patients changed therapy.
The trial is experimental both in design and approach for patients with poor therapy options. The trial addresses an area with little biological sensitivity data available. The opportunity for organoid data is valuable as it is an unmet clinical need – it has been used to idetnify that the drugs currently used do not kill off the metastases.
The trial has previously applied for the 2018 AGITG Innovation Fund and the 2018 MRFF Grant, to no success. It was noted that the trial poses potential to be rolled out to a larger-scale study in the future.
The five sites currently identified to OXTOX will inform the composition of the trial’s Trial Management Committee (TMC). Dr Lorraine Chantrill was nominated to be considered for the TMC and Wollongong Hospital was identified as a potential trial site. The OXTOX Trial Management Committee was supported by the Working Party.
Concept Development Opportunities and Funding Models
The following funding and research development opportunities were noted: